백반증을 동반한 아토피피부염 환자에서 Cyclosporine 투여 후 백반증이 호전된 증례 = Vitiligo Lesions Improved after Oral Cyclosporine in a Patient with Vitiligo and Atopic Dermatitis

다국어 초록 (Multilingual Abstract)

Vitiligo is an acquired cutaneous disorder of pigmentation with no definite etiology. Although there are a number of treatment modalities including phototherapy, topical corticosteroids and topical immunomodulators, few studies on the effect of systemic cyclosporine for the treatment of vitiligo have been conducted. We have experienced the improvement of vitiligo lesions after 8 months of systemic administration of cyclosporine (2.5~3.3 mg/kg/day) in a patient with vitiligo and atopic dermatitis. We believe this case report warrants further investigations of cyclosporine for the treatment of vitiligo in terms of mechanisms and clinical outcomes as well. (Korean J Dermatol 2012;50(2):159~162)

참고문헌 (Reference)

1 Tjioe M, "Topiccal macrolide immunomodulators: a role in the treatment of vitiligo?" 7 : 7-12, 2006

2 Grimes PE, "Topical tacrolimus for repigmentation of vitiligo" 47 : 789-791, 2002

3 Boone B, "Topical pimecrolimus in the treatment of vitiligo" 17 : 55-61, 2007

4 Armor KT, "The use of cyclosporine in dermatology: Part I" 63 : 925-946, 2010

5 Taieb A, "Tacrolimus and the pigmentary system" 210 : 177-178, 2005

6 Smith DA, "Repigmentation of vitiligo with topical tacrolimus" 205 : 301-303, 2002

7 Passeron T, "Physiopathology and genetics of vitiligo" 25 : 63-68, 2005

8 Moretti S, "New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions" 15 : 87-92, 2002

9 Dell’Anna ML, "Mitochondrial impairment in peripheral blood mononuclear cells during the active phase of vitiligo" 117 : 908-913, 2001

10 Wankowicz-Kalinska A, "Immunopolarization of CD4＋ and CD8＋ T cells to Type-1-like is associated with melanocyte loss in human vitiligo" 83 : 683-695, 2003

11 Brady AJ, "Hyperpigmentation due to cyclosporine therapy" 4 : 309-310, 1989

12 Lan CC, "FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo" 153 : 498-505, 2005

13 Lan CC, "FK506 (tacrolimus) and endothelin combined treatment induces mobility of melanoblasts: new insights into follicular vitiligorepigmentation induced by topical tacrolimus on sun-exposed skin" 164 : 490-496, 2011

14 Szepietowski J, "Excess benign melanocytic naevi in renal transplant recipients" 194 : 17-19, 1997

15 Lee JY, "Effect of cyclosporine A on melanogenesis in cultured human melanocytes" 16 : 504-508, 2003

16 Young-Sook Lee, "Downregulation of NFAT2 promotes melanogenesis in B16 melanoma cells" 대한해부학회 43 (43): 303-309, 2011

17 Rebora A, "Cyclosporin A-induced hair darkening" 38 : 229-230, 1999

18 Ozkaya-Bayazit E, "Bullous acral erythema and concomitant pigmentation on the face and occluded skin" 14 : 139-140, 2000

19 Stinco G, "An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo" 19 : 588-593, 2009